StockData
Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Inc. (FHTX) income statement

FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/30
$1.83+0.04 (+2.23%)

Close on Nov 17, 2026Market cap $108.68MP/E –Yield –

Foghorn Therapeutics Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-198.0%
Net margin
-175.8%
Return on equity, FY2025
96.5%

Financial strength

Current ratio
3.36
Debt to equity
–
Debt to assets
–
Cash to current liabilities
134.6%

Valuation

P/E ratio
–
Price to sales
2.96
Price to book
–
Dividend yield
–

See a number that looks wrong?